The extent to which gastro-intestinal (G.I.) tumours are hormonally controlled is unknown. However, a number of GIassociated peptide hormones, including gastrin, have been shown to increase the growth of gut tumours (Review, Townsend et al., 1987) . In addition, gastrin receptors (G.R.) have been found on pancreatic (Scemama et al., 1987) , gastric (Weinstock & Baldwin, 1988) and colo-rectal (Upp et al., 1989) tumours. It is possible that agents which bind to GR may have a therapeutic role, preventing growth stimulation by the ligand, in the same way that tamoxifen, an oestrogen receptor antagonist, prevents growth stimulation of breast cancer by oestradiol (Furr & Jordan, 1984) .
In this study, the effect of the GR antagonist, CR2093 was examined on the basal and gastrin-stimulated growth of the following GR-positive xenografts; AR42J (rat pancreatic), MKN45 (human gastric) and C523 (human colo-rectal).
Materials and methods
Tumour cell line AR42J, a rat pancreatic tumour cell line (Jessop & Hay, 1980) , MKN45, a human gastric tumour line (Motoyama & Watanabe, 1985) and C523 a human colo-rectal tumour line (derived in the Cancer Research Campaign Laboratories, Nottingham), were maintained in vitro in RPMI culture medium (Flow Labs., Irvine, Scotland) containing 10% heatinactivated foetal calf serum (FCS, Gibco, Paisley, Scotland) .
Xenografts were initiated at a subcutaneous (s.c.) site on the left hand flank of immuno-compromised male nude mice (Harlan-Olac, Bicester, UK) by injection of cells (5 x 106 to 107 cells per site). After approximately 14 days, tumour growth was evident, which reached maximal size after 3 to 4 weeks.
GR antagonist, CR2093
The GR antagonist CR2093 (a non-peptidic glutamic acid derivative; R-4-(3-chlorobenzamido)-5-(3,3-dimethyl butylamino)-5-oxo-pentanoic acid; M.W. 368.87) was provided by Rotta Research Laboratories, Milan, Italy. CR2093 has been shown to bind to guinea pig gastric glands and to mouse cerebral cortex membranes at a concentration range of 10-7 M to 10-' M. In addition, in vivo, CR2093 antagonised in a dose-dependent fashion, gastric acid secretion in perfused, anaesthetised rat stomach, induced by pentagastrin. The CR2093 dose that reduced gastric stimulated secretion by 50% and shown to be non-toxic, was 40 mg kg-' which was the dose chosen for the in vivo experiments performed in the present study (L.C. Rovati: Communication to the Society for Drug Research, London, March 1991). The antagonist was dissolved in sterile distilled water containing stoichiometric quantities of sodium hydroxide and stored at -20°C at 1 mg ml for the in vitro study from which it was infused into culture medium at the required concentration. For in vivo studies, CR2093 was dissolved in 0.9% saline, with stoichiometric quantities of sodium hydroxide.
Gastrin receptor binding studies Cells were harvested from semi-confluent cell monolayers with 0.025% EDTA (Sigma, Poole, Dorset, UK) for AR42J and C523 cells and 0.025% trypsin (Sigma), 0.5% EDTA for MKN45 cells. The cells were then washed in minimal Eagles medium (MEM, Flow Labs) containing 0.5% Bovine Serum Albumin (BSA, Sigma) and 10 jig ml-' aprotinin (Sigma), and aliquoted into tubes at 2 x 105 cells per tube. '25I-gastrin-17 ('25I-G17, NEN-Dupont, Stevenage, Herts, UK (Specific activity 2200 Ci mmol-1)) at a final concentration between 5 x 10-"°and 10-9 M was premixed with either CR2093 (10-3 to 10-7 M) or gastrin-17 (G17, Sigma, 10-5 M) and added to the cells (three replicates were performed per concentration). The cells were vortexed and incubated for 1 h at 22°C, before being washed in ice cold MEM by centrifugation and associated radio-activity counted on a y-counter. Results were calculated as the % inhibition of specific '251I-G17 binding (specific binding was measured when cells were incubated with '25I-G17, in the presence of 10-5 M G17).
Scatchard analyses (Scatchard, 1948) were performed on all three cell lines. '25I-G17 at concentrations between 5 x 10-" and 10-9 M was incubated with/without 10-5 M unlabelled G17 as described above. Specific binding was calculated at each '251-G17 concentration and the receptor affinity (Kd) and maximal receptor capacity (Bmax) calculated from a ligand pc curve-fitting programme (Munson & Rodbard, 1980 into 40 nude mice. The animals were then randomised into four experimental groups of ten mice.
The effect of CR2093 administration was examined on basal and gastrin-stimulated growth. Human G17 was administered via osmotic mini-pumps (Model 2002, Alzet, Charles River, Kent, UK) at a concentration of 10 tig mouse-day-' which pumped G17 from day 0 to day 17. Control mice received sterile distilled water (which was also delivered by osmotic mini-pumps).
CR2093 was administered at a dose of 40 mg kg-' day-', intravenously (i.v.) , every morning from day 0 and therapy was terminated at day 20. Control mice received 0.9% saline. Tumour growth was monitored three times weekly by an experienced, independent observer by measurement of the largest perpendicular diameters of the tumour, from which the cross-sectional areas were derived.
The four animal groups were as follows:
Group I Water containing pumps, saline i.v. Group II G17 containing pumps, saline i.v. Group III Water containing pumps, CR2093, i.v. Group IV G17 containing pumps, CR2093, i.v.
In vivo biodistribution of CR2093
The serum levels of CR2093 following i.v. administration were followed for 24 h. CR2093 (40 mg kg-') was injected into 12 nude mice and three animals were killed after 1, 3, 7 and 24 h and blood collected by cardiac puncture. After allowing for clot formation, serum was removed for analysis. In parallel, animals injected i.v. with saline (control treatment) were also killed and bled at the same time points. For analysis of CR2093 levels in the serum, a GR binding assay was performed with AR42J cells. The neat sera were admixed with 5 x 10-0M '25I-G17 and incubated with AR42J cells in suspension (as described in the GR binding studies section). Inhibition of binding of '25I-G17 to AR42J by the sera was measured and related to a standard curve in which known concentrations of CR2093 were diluted in pooled nude mouse serum and competed with 5 x 10-10M 125I-G17 for binding to AR42J cells. The standard curve was used to relate the inhibition achieved with unknown sera to a CR2093 concentration. The levels of inhibition of binding of 125I-G17 were measured in the sera from the saline controls and 100% inhibition of '25I-G17 binding was measured by displacement with a saturating dose of G17 (10-5 M) diluted in mouse sera.
UKCCCR Guidelines were adhered to in all animal experimentation.
Statistics
For the GR studies, statistical significance was determined by the Student's t-test. For the in vivo studies, due to the nonparametric distribution of the data, the Mann Whitney U Wilcoxon Rank Sum W statistical test was performed, as analysed with the SPSS/PC + statistical package for the IBM PC.
Results

Gastric receptor binding studies
The Kd and Bmax of GR on the three cell lines were calculated by Scatchard analysis (Figure 1 ). The Kd and Bmax for AR42J were 4.6 x 10-10 M and 5.5 fmols per I05 cells, for MKN45, 1.2 x 10-9 M and 12.8 fmols per 105 cells and for C523, 2.2 x 10-10 M and 0.37 fmols per 105 cells, respectively.
The ability of CR2093 to displace '25I-G17 from GR was One hour after the i.v. injection of CR2093 the serum level was 7.0 x 10-5 M which had dropped to 4.0 x 10-5 M after 3 h, 5.4 x 10-7 M after 7 h and <2.7 x 10-7 M after 24 h (Table I) . Serum from mice treated with saline did not complete with '25I-G17 for binding to GR on AR42J.
The effect of CR2093 on the basal and GI 7-stimulated growth of AR42J xenografts Figure 3 (a and b) shows the mean cross-sectional areas of AR42J xenografts in the four groups of experimental animals. At the termination of the experiment (day 24), Group II had significantly greater cross-sectional tumour areas when compared to Group I (P = 0.0158, Figure 3a) . In comparison, Group IV had significantly lowered cross-sectional tumour areas when compared to both Group I (P = 0.0166) and Group II (P = 0.0109). However, the cross sectional tumour areas of Group III were not significantly different from that of Group I (Figure 3b) .
The final mean tumour weights obtained at day 24 are shown in Figure 4a . The tumour weights of Group II were significantly elevated when compared to Group I (P = 0.033). The tumour weights of Group IV were significantly lowered from Group II (P = 0.0355) and Group I (P = 0.0403). However, the tumour weights of Group III were not significantly different from those of Group I.
The final mean body weights of the experimental animals (minus the tumours) were the same in all experimental groups (Figure 4b ). Figure 4 Effect of CR2093 on the basal and gastrin-stimulated growth of AR42J xenografts. a, Final mean tumour weights at the termination of the experiment (day 24). *P = 0.033 when compared to Group I, **P = 0.0355 from Group II and P = 0.0403 from Group I. All statistical analyses were determined by the Mann Whitney U test. (n = 10 animals/group). The s.e. of the mean is shown by the error bars. b, Final mean animal weights at day 24 (body weight minus tumour weight). (n = ten animals per group). The s.e. of the mean is shown. concentrations achieved in the serum for at least the first 3 h were between 7 and 4 x 10-M which were competing with fasting serum G17 levels of 1.55 x 10-`M which are known to be attained when delivering G17 by osmotic mini pump at 10 lOg mouse day (Watson et al., 1989 The trend in IC5os indicated that the higher the affinity of the GR the greater the CR2093 concentration required to compete with G17 for binding to the GR. This was reflected in the in vivo studies in that the serum levels of CR2093 attained competed with G17 and inhibited G17-stimulated growth of MKN45 and AR42J of Kds 1.2 x 10-9 M and 6.6 x 10`0 respectively but failed to inhibit the G17 stimulated growth of C523 which has GR of Kd 2.2 x 1010 M.
Future studies will be aimed at increasing the in vivo dosage administered to animals bearing C523 xenografts to try and achieve competitive serum levels of CR2093.
By 7 h, the serum level of CR2093 had dropped to 5.4 x I0-M which may not have competed with serum G17 levels (achieved by the osmotic mini-pump) for GR binding (50% inhibition of 5 x 10-`oM G17 binding was achieved at CR2093 concentrations > 5 x 10-5 M for all three cell lines, Figure 2 ). This indicates the inhibition of G17-stimulated AR42J and MKN45 xenograft growth may have been achieved by serum CR2093 levels which were high enough to compete with G17 for GR binding for up to 7 h each day. Relating this to the clinical situation, it may be that long term maintenance of serum CR2093 concentrations may not be essential for a therapeutic effect, providing the peak serum concentration attained is sufficiently high.
The level of inhibition of G17-stimulated AR42J growth achieved with CR2093 was similar to that achieved with the more potent benzodiazepine GR antagonist, L-365,260 (Bock et al., 1989) examined in the same xenograft system (IC50 of L-365,260, was 4.5 x 10-M when competing with 5 x 10-10 M '25I-G17) and administered at a dose of 5 mg kg-day- (Watson et al., 1991b GR. In the present study, the effects of G17 and CR2093 on the number and affinity of GR, alone and in combination were not investigated for the three cell lines. Future studies aimed at measuring such parameters may shed some light on the possible mechanism responsible for the inhibitory effects of the CR2093/G17 combination on AR42J xenografts.
It has been shown that patients with colo-rectal and gastric tumours may have elevated serum gastrin levels (Smith et al., McGuigan & Trudeau, 1973) . In addition, human GI tumour cells are capable of producing gastrin in an autocrine/paracrine manner (Watson et al., 1991a; Hoosein et al., 1990; Baldwin et al., 1990) . Thus GR antagonists, in patients with GI tumours may have to compete with high levels of serum gastrin and unknown concentrations of tumour-associated gastrin. In the present study, it has been shown that gastrin receptor antagonists can block the growth-promoting effects of elevated serum gastrin levels in 2/3 GI tumour xenograft models. In addition the gastrin and cholecystokinin (CCK) receptor antagonists, proglumide (Hoosein et al., 1988) and CR1409 (lorglumide) (Watson et al., 1989) respectively inhibited the basal growth of GI tumours cells in which GI peptide hormones may be acting in an autocrine/paracrine manner.
In conclusion, potent GR antagonists (with respect to receptor binding) with favourable pharmokinetics may be therapeutically effective in patients with GR positive GI tumours.
